Pricing
  1. JP-listed companies
  2. Chordia Therapeutics,Inc
  3. Financials
  4. Earnings per share

Chordia Therapeutics,Inc (190A)

Market cap
¥8.9B
P/E ratio
-4.5x
Chordia Therapeutics discovers and develops innovative small-molecule cancer drugs that target RNA regulatory stress in cancer cells for pharmaceutical partners.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEarnings per share (JPY)YoY (%)
Aug 31, 2025-26-16.33%
Aug 31, 2024-31.1-885.61%
Aug 31, 20234-109.95%
Aug 31, 2022-39.8-98.68%
Aug 31, 2021-3,016.6-56.18%
Aug 31, 2020-6,884.7+39.72%
Aug 31, 2019-4,927.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat